Darolutamide Demonstrates Significant HRQoL Benefits in mCSPC Patients

Recent post-hoc analyses from the ARANOTE Phase III trial, presented at ASCO 2025, underscored the quality-of-life advantages associated with darolutamide (Nubeqa) in combination with ADT. The analyses revealed a delay of approximately 5.1 months in the deterioration of health-related quality of life (HRQoL), as measured by FACT-P scores, compared to ADT alone (16.6 vs 11.5 months; HR 0.76). Additionally, darolutamide significantly postponed pain progression (HR 0.72), improving patients' social, functional, and urinary well-being without a corresponding increase in adverse events. These findings emphasize darolutamide's favorable impact beyond clinical efficacy, highlighting its potential role in enhancing patient-centered care in mCSPC.

Citation: Bayer, May 2025. Available at: https://www.bayer.com/en/us/news-stories/nubeqa-androgen-receptor-inhibitor

Implication: Improved quality-of-life metrics may influence therapy selection, focusing on patient well-being alongside clinical outcomes.